Print Page Close Window|
Investors and Media
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases.
Recent NewsJun 22, 2017Idera Announces FDA Orphan Drug Designation for IMO-2125 for the Treatment of MelanomaRead MoreJun 05, 2017Idera to Present at the Jefferies 2017 Healthcare ConferenceRead MoreMay 04, 2017Idera Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate UpdateRead More
|There are currently no events scheduled.|
Data provided by Nasdaq. Minimum 15 minutes delayed.